Aimmune Therapeutics (AIMT) Lifted to “Hold” at BidaskClub

BidaskClub upgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a sell rating to a hold rating in a report issued on Friday morning.

A number of other equities analysts have also issued reports on the stock. ValuEngine lowered shares of Aimmune Therapeutics from a strong-buy rating to a buy rating in a research report on Wednesday, January 2nd. Goldman Sachs Group set a $36.00 target price on shares of Aimmune Therapeutics and gave the stock a hold rating in a research report on Thursday, December 20th. Wedbush set a $80.00 target price on shares of Aimmune Therapeutics and gave the stock a buy rating in a research report on Thursday, December 13th. Roth Capital set a $80.00 target price on shares of Aimmune Therapeutics and gave the stock a buy rating in a research report on Thursday, December 13th. Finally, Credit Suisse Group set a $40.00 target price on shares of Aimmune Therapeutics and gave the stock a buy rating in a research report on Wednesday, December 12th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $48.90.

NASDAQ:AIMT opened at $25.63 on Friday. Aimmune Therapeutics has a 12 month low of $21.38 and a 12 month high of $42.00. The company has a market capitalization of $1.55 billion, a PE ratio of -9.82 and a beta of -0.07.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Thursday, November 8th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.03. On average, sell-side analysts forecast that Aimmune Therapeutics will post -3.6 EPS for the current year.

In related news, insider Jayson Donald Alexander Dallas bought 3,650 shares of the company’s stock in a transaction that occurred on Monday, November 19th. The shares were acquired at an average price of $27.56 per share, with a total value of $100,594.00. Following the completion of the transaction, the insider now owns 63,600 shares of the company’s stock, valued at approximately $1,752,816. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 14.70% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Carroll Financial Associates Inc. acquired a new stake in Aimmune Therapeutics during the fourth quarter worth $28,000. Vanguard Group Inc boosted its stake in Aimmune Therapeutics by 3.9% during the third quarter. Vanguard Group Inc now owns 3,579,306 shares of the biotechnology company’s stock worth $97,643,000 after buying an additional 135,159 shares in the last quarter. Vanguard Group Inc. boosted its stake in Aimmune Therapeutics by 3.9% during the third quarter. Vanguard Group Inc. now owns 3,579,306 shares of the biotechnology company’s stock worth $97,643,000 after buying an additional 135,159 shares in the last quarter. Rehmann Capital Advisory Group boosted its stake in Aimmune Therapeutics by 2,242.4% during the third quarter. Rehmann Capital Advisory Group now owns 6,465 shares of the biotechnology company’s stock worth $237,000 after buying an additional 6,189 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in Aimmune Therapeutics by 25.2% during the third quarter. Teachers Advisors LLC now owns 103,078 shares of the biotechnology company’s stock worth $2,812,000 after buying an additional 20,751 shares in the last quarter. Hedge funds and other institutional investors own 75.02% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Recommended Story: Stock Symbol

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit